Consensus AB Science

Equities

AB

FR0010557264

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-04-25 am EDT			5-day change	1st Jan Change
1.884 ^EUR	-2.89%		-5.33%	-47.00%

Apr. 04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
Apr. 03	AB Science: reconsideration possible for masitinib in ALS	CF

Evolution of the average Target Price on AB Science

Price target over the last 5 years

History of analyst recommendation changes

cecc60f73404de9.bptqJp9KSgwDwh5U3YTb5zYuCSmdcqXyINegt30DPiY.WtMFUvN_KzRCpHMSjuCMoEcZTmDTKP2wRJCR2RJRX0oIyTVW2R0CPnePJg~c14f4da128cb26f57f94ab4d27131e72

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates	20-12-04	MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30	15-05-05	GL

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.884 EUR

Average target price

6.895 EUR

Spread / Average Target

+265.98%

High Price Target

10 EUR

Spread / Highest target

+430.79%

Low Price Target

3.79 EUR

Spread / Lowest Target

+101.17%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar